Adnan KhanAdnanProduct & AI
San Francisco Bay Area
Get in touch

Source note3 min read

Finding H. pylori in the Fine Print: Evidence-Linked Multi-Agent Case Finding from Gastric Biopsy Reports

Source

arXiv

arxiv.org/abs/2607.06435v1

Read the source

Source

  • Source name: arXiv
  • Source kind: paper
  • Authors / organization: Yufan Wang, Anit Kumar Sahu, Yan Fei Ng, Daniel Kang, Shayan Vassef, Soorya Ram Shimgekar, Koustuv Saha, Piyum Zonooz, Navin Kumar, Chee Leong Cheng, Li Yan Khor
  • Venue: arXiv: cs.AI
  • Published: 2026-07-07
  • Collected: 2026-07-08
  • URL: http://arxiv.org/abs/2607.06435v1
  • PDF: https://arxiv.org/pdf/2607.06435v1
  • DOI: UNKNOWN

Plain-Language Brief

Researchers evaluated a system called nMAS for extracting information about Helicobacter pylori infections from gastric biopsy reports. The system correctly identified the presence of H. pylori and associated conditions 98.61% of the time, which could significantly reduce the time required for manual review.

What the Document Says

  • The study was a retrospective evaluation of nMAS on 54 de-identified gastric biopsy pathology reports.
  • Four binary fields were evaluated: gastric/stomach biopsy, biopsy status, H. pylori positivity, and H. pylori-associated gastritis.
  • nMAS correctly classified 213 out of 216 feature-case decisions, resulting in an overall accuracy of 98.61%.
  • A UMA-style MiniMax M2.5 comparator produced similar results.
  • The nMAS system provides report-level outputs with supporting source sentences for traceability.
  • Under a hypothetical scenario, using nMAS could save up to 81.9 staff-hours and approximately USD~6,100 in potential staff-time.

Key Concepts Mentioned

  • Helicobacter pylori
  • gastric biopsy reports
  • nMAS
  • H. pylori positivity
  • H. pylori-associated gastritis

Claims Made by the Document

  • nMAS correctly classified 98.61% of the cases.
  • A UMA-style MiniMax M2.5 comparator produced similar results.

Evidence Used

  • Across 216 feature-case decisions, nMAS correctly classified 213... A separately implemented UMA-style MiniMax M2.5 comparator produced similar aggregate and per-field classification metrics.

Methods / Approach

  • Retrospective pilot evaluation
  • Use of the Nimblemind Multi-Agent System (nMAS)

Limitations Stated by the Authors

  • Larger multi-institutional studies should evaluate evidence-span correctness, clinician verification time, and generalizability.

Limitations Noted by the Agent

Agent interpretation — not from the source.

  • The text does not provide information on the specific methodology used in the study or any potential biases that may have been introduced.

Open Questions

  • What is the evidence-span correctness of nMAS?
  • What is the clinician verification time using nMAS?

Notes for Future Q&A

May include interpretation. Labeled where it does.

  • The text mentions a hypothetical scenario for savings, but it does not provide actual data on the time saved or the number of reports reviewed.

Raw Abstract / Excerpt

Data from Singapore indicated that about 31% of the population had evidence of Helicobacter pylori infection. Persistent H. pylori infection is associated with chronic active gastritis and peptic ulcer disease, and its eradication is key to gastric cancer prevention. However, evidence supporting \textit{H. pylori} positivity and H. pylori-associated gastritis may be distributed across heterogeneous coded and free-text report fields and may require contextual interpretation of assertion and negation, limiting keyword search, and making manual review difficult to scale. We conducted a retrospective pilot evaluation of the Nimblemind Multi-Agent System (nMAS), a field-name-driven, evidence-linked extraction workflow, using 54 de-identified gastric biopsy pathology reports from a large healthcare system in Singapore. Four clinician-scoped binary fields were evaluated: gastric/stomach biopsy, biopsy status, H. pylori positivity, and H. pylori-associated gastritis. Across 216 feature-case decisions, nMAS correctly classified 213, corresponding to 98.61% overall accuracy. A separately implemented UMA-style MiniMax M2.5 comparator produced similar aggregate and per-field classification metrics. Although predictive performance was similar, nMAS maintained unified report-level outputs with supporting source sentences; the demonstrated contribution is therefore workflow integration and traceability rather than predictive superiority. Under an illustrative, unmeasured scenario, reviewing 1,000 reports at five minutes per manual review versus five seconds per evidence-linked verification would reduce review time from 83.3 to 1.4 staff-hours, corresponding to 81.9 staff-hours and about USD~6,100 in potential staff-time value. Larger multi-institutional studies should evaluate evidence-span correctness, clinician verification time, and generalizability.